Product Details
| Alternative Name: | Interleukin-33, NF-HEV, IL-1F11 |
| |
| MW: | ~18kDa |
| |
| Source: | Produced in E. coli. Untagged mouse IL-33 (aa 109-266). |
| |
| UniProt ID: | Q8BVZ5 |
| |
| Concentration: | 0.1mg/ml after reconstitution. |
| |
| Formulation: | Lyophilized. Contains PBS. |
| |
| Purity: | ≥95% (SDS-PAGE) |
| |
| Endotoxin Content: | <0.1EU/µg purified protein (LAL test; Associates of Cape Cod). |
| |
| Specificity: | Binds to mouse and human ST2. |
| |
| Reconstitution: | Reconstitute with 100µl sterile distilled water. Further dilutions should be made with medium containing 5% fetal calf serum. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. |
| |
| Handling: | Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C. |
| |
| Scientific Background: | IL-33 is a member of the IL-1 family. It is involved in T helper type 2 response via the activation of its receptor ST2 (IL-1RL1) driving the production of Th2-associated cytokines. The stimulation of ST2 by IL-33 induces the NF-κB and MAPK pathways. The mouse IL-33 protein is expressed with a prodomain (aa 1-108) which is cleaved to produce the 18kDa mature protein (109-266). Historical data has shown that IL-33 activates mouse and human ST2-dependent NF-κB pathway and induces IL-6 production in P815 mastocytoma cells and in bone marrow derived mast cells. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
SDS-PAGE analysis: Lane 1: MW Marker; Lane 2: 1.0ug of purified IL-33 (mouse), (recombinant).
Western Blot analysis: Lane 1: MW Marker; Lane 2: 100ng of purified IL-33 (mouse), (recombinant) protein probed with IL-33 mAb (Prod. no. ALX-804-840PF-C100) at 0.5ug/ml.
Please mouse over
Product Literature References
Treatment with interleukin-33 is non-toxic and protects retinal pigment epithelium in an ageing model of outer retinal degeneration: A.J. Clare, et al.; J. Cell. Mol. Med.
24, 13456 (2020),
Abstract;
Full Text
Endotoxin tolerance in mast cells, its consequences for IgE-mediated signalling, and the effects of BCL3 deficiency: M. Poplutz, et al.; Sci. Rep.
7, 4534 (2017),
Abstract;
Full Text
Interleukin-33 regulates tissue remodelling and inhibits angiogenesis in the eye: S. Theodoropoulou, et al.; J. Pathol.
241, 45 (2017),
Abstract;
Full Text
IL-33 Drives Eosinophil Infiltration and Pathogenic Type 2 Helper T-Cell Immune Responses Leading to Chronic Experimental Ileitis: C. De Salvo, et al.; Am. J. Pathol.
186, 885 (2016),
Application(s): Experimental in Vivo Studies,
Abstract;
Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and Kit-independent pathways: R. Saluja, et al.; J. Biol. Regul. Homeost. Agents.
28, 575 (2014),
Abstract;
The novel cytokine interleukin-33 activates acinar cell proinflammatory pathways and induces acute pancreatic inflammation in mice: D. Kempuraj, et al.; PLoS One
8, e56866 (2013),
Abstract;
Full Text
IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells: S. Ali, et al.; PNAS
104, 18660 (2007),
Abstract;
General Literature References
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines: J. Schmitz, et al.; Immunity
23, 479 (2005),
Abstract;
Related Products
